The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | RATIONALE-302: PD-L1 concordance in tislelizumab outcomes for ESCC
Ken Kato, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, presents a retrospective investigation into the concordance between three PD-L1 scoring methods and their association with clinical outcomes in RATIONALE-302 (NCT03430843), a Phase III study comparing the anti-PD-1 antibody tislelizumab to investigator-chosen chemotherapy (ICC) for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC). The study examined the tumor area positivity (TAP) score, combined positive score (CPS), and tumor cell (TC) score at various cutoffs. The TAP score and CPS demonstrated substantial concordance, suggesting they may be interchangeable for clinical measurement of PD-L1 expression in ESCC patients. The overall survival benefit with tislelizumab vs ICC was generally similar across PD-L1 subgroups. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
